American Journal of Cardiology
Volume 106, Issue 3 , Pages 360-368 , 1 August 2010

Pathogenesis of Myocardial Ischemia-Reperfusion Injury and Rationale for Therapy

  • Aslan T. Turer, MD, MHS

      Affiliations

    • Department of Internal Medicine (Cardiology), University of Texas Southwestern Medical Center, Dallas, Texas
    • Corresponding Author InformationCorresponding author: Tel: 214-645-7558; fax: 214-645-7501
    • ,
  • Joseph A. Hill, MD, PhD

      Affiliations

    • Department of Internal Medicine (Cardiology), University of Texas Southwestern Medical Center, Dallas, Texas
    • Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, Texas

Received 31 January 2010 ,Revised 22 March 2010 ,Accepted 22 March 2010.

References 

  1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics—2010 update (A report from the American Heart Association). Circulation. 2009;121:e1–e170
  2. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol. 1960;70:68–78
  3. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword?. J Clin Invest. 1985;76:1713–1719
  4. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124–1136
  5. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol. 2005;288:H971–H976
  6. Bond JM, Herman B, Lemasters JJ. Protection by acidotic pH against anoxia/reoxygenation injury to rat neonatal cardiac myocytes. Biochem Biophys Res Commun. 1991;179:798–803
  7. Lemasters JJ, Bond JM, Chacon E, Harper IS, Kaplan SH, Ohata H, et al. The pH paradox in ischemia-reperfusion injury to cardiac myocytes. EXS. 1996;76:99–114
  8. Tani M, Neely JR. Role of intracellular Na+ in Ca2+ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts (Possible involvement of H+-Na+ and Na+-Ca2+ exchange). Circ Res. 1989;65:1045–1056
  9. Bush LR, Romson JL, Ash JL, Lucchesi BR. Effect of diltiazem on extent of ultimate myocardial injury resulting from temporary coronary artery occlusion in dogs. J Cardiovasc Pharmacol. 1982;4:285–296
  10. du Toit EF, Opie LH. Modulation of severity of reperfusion stunning in the isolated rat heart by agents altering calcium flux at onset of reperfusion. Circ Res. 1992;70:960–967
  11. Krause S, Hess ML. Characterization of cardiac sarcoplasmic reticulum dysfunction during short-term, normothermic, global ischemia. Circ Res. 1984;55:176–184
  12. Kaplan P, Hendrikx M, Mattheussen M, Mubagwa K, Flameng W. Effect of ischemia and reperfusion on sarcoplasmic reticulum calcium uptake. Circ Res. 1992;71:1123–1130
  13. Kusuoka H, Porterfield JK, Weisman HF, Weisfeldt ML, Marban E. Pathophysiology and pathogenesis of stunned myocardium (Depressed Ca2+ activation of contraction as a consequence of reperfusion-induced cellular calcium overload in ferret hearts). J Clin Invest. 1987;79:950–961
  14. Nayler WG. The role of calcium in the ischemic myocardium. Am J Pathol. 1981;102:262–270
  15. Zimmerman ANE, Daems W, Hulsmann WC, Snijder J, Wisse E, Durrer D. Morphological changes of heart muscle caused by successive perfusion with calcium-free and calcium-containing solutions (calcium paradox). Cardiovasc Res. 1967;1:201–209
  16. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003;4:552–565
  17. Kim JS, Jin Y, Lemasters JJ. Reactive oxygen species, but not Ca2+ overloading, trigger pH- and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2006;290:H2024–H2034
  18. Rajesh KG, Sasaguri S, Suzuki R, Maeda H. Antioxidant MCI-186 inhibits mitochondrial permeability transition pore and upregulates Bcl-2 expression. Am J Physiol Heart Circ Physiol. 2003;285:H2171–H2178
  19. Schild L, Reiser G. Oxidative stress is involved in the permeabilization of the inner membrane of brain mitochondria exposed to hypoxia/reoxygenation and low micromolar Ca2+. FEBS J. 2005;272:3593–3601
  20. Thompson-Gorman SL, Zweier JL. Evaluation of the role of xanthine oxidase in myocardial reperfusion injury. J Biol Chem. 1990;265:6656–6663
  21. Xia Y, Zweier JL. Substrate control of free radical generation from xanthine oxidase in the postischemic heart. J Biol Chem. 1995;270:18797–18803
  22. Zorov DB, Juhaszova M, Yaniv Y, Nuss HB, Wang S, Sollott SJ. Regulation and pharmacology of the mitochondrial permeability transition pore. Cardiovasc Res. 2009;83:213–225
  23. Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med. 2000;192:1001–1014
  24. Loke KE, McConnell PI, Tuzman JM, Shesely EG, Smith CJ, Stackpole CJ, et al. Endogenous endothelial nitric oxide synthase-derived nitric oxide is a physiological regulator of myocardial oxygen consumption. Circ Res. 1999;84:840–845
  25. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;2:1057–1058
  26. Ma XL, Weyrich AS, Lefer DJ, Lefer AM. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res. 1993;72:403–412
  27. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A. 1990;87:1620–1624
  28. Wang P, Zweier JL. Measurement of nitric oxide and peroxynitrite generation in the postischemic heart (Evidence for peroxynitrite-mediated reperfusion injury). J Biol Chem. 1996;271:29223–29230
  29. Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T, et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res. 2007;100:914–922
  30. Wang ZV, Rothermel BA, Hill JA. Autophagy in hypertensive heart disease. J Biol Chem. 2010;285:8509–8514
  31. Chao W. Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol. 2009;296:H1–H12
  32. Busche MN, Pavlov V, Takahashi K, Stahl GL. Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin. Am J Physiol Heart Circ Physiol. 2009;297:H1853–H1859
  33. Shernan SK, Collard CD. Role of the complement system in ischaemic heart disease: potential for pharmacological intervention. BioDrugs. 2001;15:595–607
  34. Yang Z, Day YJ, Toufektsian MC, Xu Y, Ramos SI, Marshall MA, et al. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation. 2006;114:2056–2064
  35. Kobara M, Sunagawa N, Abe M, Tanaka N, Toba H, Hayashi H, et al. Apoptotic myocytes generate monocyte chemoattractant protein-1 and mediate macrophage recruitment. J Appl Physiol. 2008;104:601–609
  36. Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496–1508
  37. Brosh D, Assali AR, Mager A, Porter A, Hasdai D, Teplitsky I, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol. 2007;99:442–445
  38. Henriques JP, Zijlstra F, van 't Hof AW, de Boer MJ, Dambrink JH, Gosselink M, et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation. 2003;107:2115–2119
  39. Gibson CM, Cannon CP, Murphy SA, Marble SJ, Barron HV, Braunwald E. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation. 2002;105:1909–1913
  40. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54:281–292
  41. Okamura A, Ito H, Iwakura K, Kawano S, Inoue K, Maekawa Y, et al. Detection of embolic particles with the Doppler guide wire during coronary intervention in patients with acute myocardial infarction: efficacy of distal protection device. J Am Coll Cardiol. 2005;45:212–215
  42. Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med. 2006;3:499–506
  43. Attarian DE, Jones RN, Currie WD, Hill RC, Sink JD, Olsen CO, et al. Characteristics of chronic left ventricular hypertrophy induced by subcoronary valvular aortic stenosis (I. Myocardial blood flow and metabolism). J Thorac Cardiovasc Surg. 1981;81:382–388
  44. Anderson PG, Allard MF, Thomas GD, Bishop SP, Digerness SB. Increased ischemic injury but decreased hypoxic injury in hypertrophied rat hearts. Circ Res. 1990;67:948–959
  45. Ferdinandy P, Szilvassy Z, Baxter GF. Adaptation to myocardial stress in disease states: is preconditioning a healthy heart phenomenon?. Trends Pharmacol Sci. 1998;19:223–229
  46. Feuvray D, Lopaschuk GD. Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. Cardiovasc Res. 1997;34:113–120
  47. Di Filippo C, Marfella R, Cuzzocrea S, Piegari E, Petronella P, Giugliano D, et al. Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes. 2005;54:803–810
  48. Neckar J, Ostadal B, Kolar F. Myocardial infarct size-limiting effect of chronic hypoxia persists for five weeks of normoxic recovery. Physiol Res. 2004;53:621–628
  49. Chen C, Chen L, Fallon JT, Ma L, Li L, Bow L, et al. Functional and structural alterations with 24-hour myocardial hibernation and recovery after reperfusion (A pig model of myocardial hibernation). Circulation. 1996;94:507–516
  50. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121–1135
  51. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. J Am Coll Cardiol. 1999;34:1711–1720
  52. Assali AR, Sdringola S, Ghani M, Denkats AE, Yepes A, Hanna GP, et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of “no reflow” phenomenon. Catheter Cardiovasc Interv. 2000;51:27–31
  53. Stoel MG, Marques KM, de Cock CC, Bronzwaer JG, von BC, Zijlstra F. High dose adenosine for suboptimal myocardial reperfusion after primary PCI: a randomized placebo-controlled pilot study. Catheter Cardiovasc Interv. 2008;71:283–289
  54. Pasceri V, Pristipino C, Pelliccia F, Granatelli A, Speciale G, Roncella A, et al. Effects of the nitric oxide donor nitroprusside on no-reflow phenomenon during coronary interventions for acute myocardial infarction. Am J Cardiol. 2005;95:1358–1361
  55. Wang HJ, Lo PH, Lin JJ, Lee H, Hung JS. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv. 2004;63:171–176
  56. Amit G, Cafri C, Yaroslavtsev S, Fuchs S, Paltiel O, Bu-Ful A, et al. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction (A randomized, double-blind, placebo-controlled clinical trial). Am Heart J. 2006;152:814–887
  57. Barcin C, Denktas AE, Lennon RJ, Hammes L, Higano ST, Holmes DR, et al. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv. 2004;61:484–491
  58. Laskey WK. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: a pilot study. Catheter Cardiovasc Interv. 2005;65:361–367
  59. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, et al. Postconditioning the human heart. Circulation. 2005;112:2143–2148
  60. Laskey WK, Yoon S, Calzada N, Ricciardi MJ. Concordant improvements in coronary flow reserve and ST-segment resolution during percutaneous coronary intervention for acute myocardial infarction: a benefit of postconditioning. Catheter Cardiovasc Interv. 2008;72:212–220
  61. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473–481
  62. Olivencia-Yurvati AH, Blair JL, Baig M, Mallet RT. Pyruvate-enhanced cardioprotection during surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2003;17:715–720
  63. Uyar I, Mansuroglu D, Kirali K, Erentug V, Bozbuga NU, Uysal G, et al. Aspartate and glutamate-enriched cardioplegia in left ventricular dysfunction. J Card Surg. 2005;20:337–344
  64. Modi P, Suleiman MS, Reeves B, Pawade A, Parry AJ, Angelini GD, et al. Myocardial metabolic changes during pediatric cardiac surgery: a randomized study of 3 cardioplegic techniques. J Thorac Cardiovasc Surg. 2004;128:67–75
  65. Walsh SR, Tang TY, Kullar P, Jenkins DP, Dutka DP, Gaunt ME. Ischaemic preconditioning during cardiac surgery: systematic review and meta-analysis of perioperative outcomes in randomised clinical trials. Eur J Cardiothorac Surg. 2008;34:985–994
  66. Fabbri A, Manfredi J, Piccin C, Soffiati G, Carta MR, Gasparotto E, et al. Systemic leukocyte filtration during cardiopulmonary bypass. Perfusion. 2001;16(suppl):11–18
  67. Koskenkari J, Rimpilainen J, Biancari F, Surcel HM, Kaukoranta P, Kiviluoma K, et al. Leukocyte depleting filter attenuates myocardial injury during elective coronary artery bypass surgery. Scand Cardiovasc J. 2005;39:358–368
  68. Leal-Noval SR, Amaya R, Herruzo A, Hernandez A, Ordonez A, Marin-Niebla A, et al. Effects of a leukocyte depleting arterial line filter on perioperative morbidity in patients undergoing cardiac surgery: a controlled randomized trial. Ann Thorac Surg. 2005;80:1394–1400
  69. Liakopoulos OJ, Schmitto JD, Kazmaier S, Brauer A, Quintel M, Schoendube FA, et al. Cardiopulmonary and systemic effects of methylprednisolone in patients undergoing cardiac surgery. Ann Thorac Surg. 2007;84:110–119
  70. Fillinger MP, Rassias AJ, Guyre PM, Sanders JH, Beach M, Pahl J, et al. Glucocorticoid effects on the inflammatory and clinical responses to cardiac surgery. J Cardiothorac Vasc Anesth. 2002;16:163–169
  71. Tassani P, Richter JA, Barankay A, Braun SL, Haehnel C, Spaeth P, et al. Does high-dose methylprednisolone in aprotinin-treated patients attenuate the systemic inflammatory response during coronary artery bypass grafting procedures?. J Cardiothorac Vasc Anesth. 1999;13:165–172
  72. De Hert S, Vlasselaers D, Barbe R, Ory JP, Dekegel D, Donnadonni R, et al. A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery. Anaesthesia. 2009;64:953–960
  73. Meco M, Cirri S, Gallazzi C, Magnani G, Cosseta D. Desflurane preconditioning in coronary artery bypass graft surgery: a double-blinded, randomised and placebo-controlled study. Eur J Cardiothorac Surg. 2007;32:319–325
  74. Julier K, da Silva R, Garcia C, Bestmann L, Frascarolo P, Zollinger A, et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology. 2003;98:1315–1327
  75. Verrier ED, Shernan SK, Taylor KM, Van de Werf F, Newman MF, Chen JC, et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA. 2004;291:2319–2327
  76. Testa L, Van Gaal WJ, Bhindi R, Biondi-Zoccai GG, Abbate A, Agostoni P, et al. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J Thorac Cardiovasc Surg. 2008;136:884–893
  77. Tardif JC, Carrier M, Kandzari DE, Emery R, Cote R, Heinonen T, et al. Effects of pyridoxal-5′-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study. J Thorac Cardiovasc Surg. 2007;133:1604–1611
  78. Alexander JH, Emery RW, Carrier M, Ellis SJ, Mehta RH, Hasselblad V, et al. Efficacy and safety of pyridoxal 5′-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial. JAMA. 2008;299:1777–1787
  79. Theroux P, Chaitman BR, Danchin N, Erhardt L, Meinertz T, Schroeder JS, et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations (Main results of the GUARDIAN trial). Circulation. 2000;102:3032–3038
  80. Boyce SW, Bartels C, Bolli R, Chaitman B, Chen JC, Chi E, et al. Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study. J Thorac Cardiovasc Surg. 2003;126:420–427
  81. Mentzer RM, Bartels C, Bolli R, Boyce S, Buckberg GD, Chaitman B, et al. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study. Ann Thorac Surg. 2008;85:1261–1270
  82. Leung JM, Stanley T, Mathew J, Curling P, Barash P, Salmenpera M, et al. An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. Anesth Analg. 1994;78:420–434
  83. Menasche P, Jamieson WR, Flameng W, Davies MK Multinational Acadesine Study Group. Acadesine: a new drug that may improve myocardial protection in coronary artery bypass grafting (Results of the first international multicenter study). J Thorac Cardiovasc Surg. 1995;110:1096–1106
  84. Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Effects of acadesine on the incidence of myocardial infarction and adverse cardiac outcomes after coronary artery bypass graft surgery. Anesthesiology. 1995;83:658–673
  85. Mangano DT, Miao Y, Tudor IC, Dietzel C. Post-reperfusion myocardial infarction: long-term survival improvement using adenosine regulation with acadesine. J Am Coll Cardiol. 2006;48:206–214
  86. Mangano DT Multicenter Study of Perioperative Ischemia (McSPI) Research Group. Effects of acadesine on myocardial infarction, stroke, and death following surgery (A meta-analysis of the 5 international randomized trials). JAMA. 1997;277:325–332
  87. Venugoapl V, Hausenloy DJ, Ludman A, Di Salvo C, Kolvekar S, Yap J, et al. Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: a randomised controlled trial. Heart. 2009;95:1567–1571
  88. Faxon DP, Gibbons RJ, Chronos NA, Gurbel PA, Sheehan F HALT-MI Investigators. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol. 2002;40:1199–1204
  89. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D, O'Neill WW, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007;297:43–51
  90. Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction (Results of the Evaluation of the Safety and Cardioprotective Effects of Eniporide in Acute Myocardial Infarction (ESCAMI) trial). J Am Coll Cardiol. 2001;38:1644–1650
  91. Boden WE, van Gilst WH, Scheldewaert RG, Starkey IR, Carlier MF, Julian DG, et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial (Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis Post-Thrombolysis (INTERCEPT)). Lancet. 2000;355:1751–1756
  92. Umemura S, Nakamura S, Sugiura T, Tsuka Y, Fujitaka K, Yoshida S, et al. The effect of verapamil on the restoration of myocardial perfusion and functional recovery in patients with angiographic no-reflow after primary percutaneous coronary intervention. Nucl Med Commun. 2006;27:247–254
  93. Vijayalakshmi K, Whittaker VJ, Kunadian B, Graham J, Wright RA, Hall JA, et al. Prospective, randomised, controlled trial to study the effect of intracoronary injection of verapamil and adenosine on coronary blood flow during percutaneous coronary intervention in patients with acute coronary syndromes. Heart. 2006;92:1278–1284
  94. Guan W, Osanai T, Kamada T, Hanada H, Ishizaka H, Onodera H, et al. Effect of allopurinol pretreatment on free radical generation after primary coronary angioplasty for acute myocardial infarction. J Cardiovasc Pharmacol. 2003;41:699–705
  95. Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, Murohara T, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation. 2005;112:1284–1288
  96. Guffin AV, Kates RA, Holbrook GW, Jones EL, Kaplan JA. Verapamil and myocardial preservation in patients undergoing coronary artery bypass surgery. Ann Thorac Surg. 1986;41:587–591
  97. Weinstein GS, Rao PS, Tyras DH. Reduction of myocardial injury with verapamil before aortic cross-clamping. Ann Thorac Surg. 1990;49:419–423
  98. Seitelberger R, Hannes W, Gleichauf M, Keilich M, Christoph M, Fasol R. Effects of diltiazem on perioperative ischemia, arrhythmias, and myocardial function in patients undergoing elective coronary bypass grafting. J Thorac Cardiovasc Surg. 1994;107:811–821
  99. Clinical study to examine the effects of erythropoietin on left ventricular function after acute myocardial infarction (HEBEIII). http://clinicaltrials.gov/ct2/show/NCT00449488Accessed on January 5, 2010
  100. EPOMI study: Erythropoietin in Myocardial Infarction. http://clinicaltrials.gov/ct2/show/NCT00648089Accessed on January 5, 2010
  101. REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Late Myocardial Infarction. http://clinicaltrials.gov/ct2/show/NCT00378352Accessed on January 5, 2010
  102. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. 2004;18:1031–1033
  103. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun. 2003;308:990–994
  104. Gao E, Boucher M, Chuprun JK, Zhou RH, Eckhart AD, Koch WJ. Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol. 2007;293:H60–H68
  105. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A. 2003;100:4802–4806
  106. Toma C, Letts DP, Tanabe M, Gorcsan J, Counihan PJ. Positive effect of darbepoetin on peri-infarction remodeling in a porcine model of myocardial ischemia-reperfusion. J Mol Cell Cardiol. 2007;43:130–136
  107. Schneider C, Jaquet K, Malisius R, Geidel S, Bahlmann E, Boczor S, et al. Attenuation of cardiac remodelling by endocardial injection of erythropoietin: ultrasonic strain-rate imaging in a model of hibernating myocardium. Eur Heart J. 2007;28:499–509
  108. Prunier F, Pfister O, Hadri L, Liang L, Del Monte F, Liao R, et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol. 2007;292:H522–H529
  109. Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation. 2008;117:2670–2683
  110. Anakinra to prevent post-infarction remodeling (VCU-ART). http://clinicaltrials.gov/ct2/show/NCT00789724Accessed on January 5, 2010
  111. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962–965
  112. Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI (POSTCON II). http://clinicaltrials.gov/ct2/show/NCT00835848Accessed on January 5, 2010
  113. Liu GS, Thornton J, Van Winkle DM, Stanley AWH, Olsson RA, Downey JM. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation. 1991;84:350–356
  114. Yang X-M, Philipp S, Downey JM, Cohen MV. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol. 2005;100:57–63
  115. Kin H, Zatta AJ, Lofye MT, Amerson BS, Halkos ME, Kerendi F, et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res. 2005;67:124–133
  116. Ki J, McIntosh R, Shen X, Lee S, Chanoit G, Criswell H, et al. Adenosine A2a and A2b receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. J Mol Cell Cardiol. 2009;47:684–690
  117. Lie RH, Hasenkam JM, Nielsen TT, Poulsen R, Sloth E. Post-conditioning reduces infarct size in an open-chest porcine acute ischemia-reperfusion model. Acta Anaesthesiol Scand. 2008;52:1188–1193
  118. Kin H, Zhao ZQ, Sun HY, Wang NP, Corvera JS, Halkos ME, et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res. 2004;62:74–85
  119. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285:H579–H588
  120. Vinten-Johansen J, Zhao ZQ, Jiang R, Zatta AJ, Dobson GP. Preconditioning and postconditioning: innate cardioprotection from ischemia-reperfusion injury. J Appl Physiol. 2007;103:1441–1448
  121. Cohen MV, Yang XM, Downey JM. The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation. 2007;115:1895–1903
  122. Cohen MV, Yang XM, Downey JM. Acidosis, oxygen, and interference with mitochondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioning's success. Basic Res Cardiol. 2008;103:464–471
  123. Weman SM, Karhunen PJ, Penttila A, Jarvinen AA, Salminen US. Reperfusion injury associated with one-fourth of deaths after coronary artery bypass grafting. Ann Thorac Surg. 2000;70:807–812
  124. Moore GW, Hutchins GM. Coronary artery bypass grafts in 109 autopsied patients (Statistical analysis of graft and anastomosis patency and regional myocardial injury). JAMA. 1981;246:1785–1789
  125. Bulkely BH, Hutchins GM. Myocardial consequences of coronary artery bypass graft surgery (The paradox of necrosis in areas of revascularization). Circulation. 1977;56:906–913
  126. Klatte K, Chaitman BR, Theroux P, Gavard JA, Stocke K, Boyce S, et al. Increased mortality after coronary artery bypass graft surgery is associated with increased levels of postoperative creatine kinase-myocardial band isoenzyme release: results from the GUARDIAN trial. J Am Coll Cardiol. 2001;38:1070–1077
  127. Costa MA, Carere RG, Lichtenstein SV, Foley DP, de Valk V, Lindenboom W, et al. Incidence, predictors, and significance of abnormal cardiac enzyme rise in patients treated with bypass surgery in the Arterial Revascularization Therapies Study (ARTS). Circulation. 2001;104:2689–2693
  128. Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med. 2008;358:784–793
  129. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med. 2008;358:771–783
  130. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008;358:2319–2331
  131. Kandzari DE, Dery JP, Armstrong PW, Douglas DA, Zettler ME, Hidinger GK, et al. MC-1 (pyridoxal 5′-phosphate): novel therapeutic applications to reduce ischaemic injury. Expert Opin Investig Drugs. 2005;14:1435–1442
  132. Mullane K. Acadesine: the prototype adenosine regulating agent for reducing myocardial ischaemic injury. Cardiovasc Res. 1993;27:43–47
  133. Gruber HE, Hoffer ME, McAllister DR, Laikind PK, Lane TA, Schmid-Schoenbein GW, et al. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside (Effects on flow, granulocytes, and injury). Circulation. 1989;80:1400–1411
  134. Forster K, Paul I, Solenkova N, Staudt A, Cohen MV, Downey JM, et al. NECA at reperfusion limits infarction and inhibits formation of the mitochondrial permeability transition pore by activating p70S6 kinase. Basic Res Cardiol. 2006;101:319–326
  135. The effect of acadesine on reducing cardiovascular and cerebrovascular adverse events in coronary artery bypass graft (CABG) surgery (study P05633AM1) (RED-CABG). http://clinicaltrials.gov/ct2/show/NCT00872001Accessed on January 5, 2010

 This work was supported by grants HL-075173, HL-080144, and HL-090842 from the National Institutes of Health, Bethesda, Maryland; grant 0640084N from the American Heart Association, Dallas, Texas; grant 7-08-MN-21-ADA from the American Diabetes Association, Alexandria, Virginia; and grant 0970518N from the AHA-Jon Holden DeHaan Foundation, Naples, Florida. Editorial support was funded by Schering-Plough Corporation, Kenilworth, New Jersey.

PII: S0002-9149(10)00781-2

doi: 10.1016/j.amjcard.2010.03.032

American Journal of Cardiology
Volume 106, Issue 3 , Pages 360-368 , 1 August 2010

Article Tools